Lilly is now pharma’s top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn’t celebrating

On April 1, the FDA approved Foundayo (orforglipron), Eli Lilly’s once-daily oral GLP-1 receptor agonist for obesity, which is the first oral GLP-1 approved for weight management and the fastest new molecular entity approval since 2002. Foundayo was cleared under the FDA’s Commissioner’s National Priority Voucher program just 50 days after filing, nearly 10 months… The post Lilly is now pharma’s top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn’t celebrating appeared first on Drug Discovery and Development.

Continue reading →